Introduction {#sec1}
============

Colorectal cancer is the fourth most common cancer and the second leading cause of cancer deaths in the world ([@ref1]). An estimated 1.09 million new colorectal cancer cases and 551 269 colorectal cancer deaths occurred in 2018 ([@ref1]). Approximately 25% of patients have metastatic disease at diagnosis and \~50--60% of patients diagnosed with colorectal cancer go on to develop metastatic disease ([@ref2]). Although the advance of surgery, radiotherapy and chemotherapy has improved the survival of colorectal cancer patients in recent years, the 5-year survival in patients with stage IV disease is 14% ([@ref3]). Response to treatment and patients' survival were variable among different population. It was known that tumor heterogeneity is a potential cause for these varied clinical outcomes ([@ref4]). Since colorectal cancer is known to be a heterogeneous disease with diverse molecular alterations, which involve in biological tumor progression. Thus, a precise molecular marker could be used to predict patients' survival or monitor cancer recurrence, which is urgently needed.

*c-MYC*, a proto-oncogene located on chromosome 8q24, is involved with regulating cell proliferation, differentiation and apoptosis ([@ref5]). In solid tumors, such as breast, ovary and prostate, *c-MYC* amplification has been documented to be related to lymph node metastasis, recurrence and disease progression to a variable degree ([@ref6]). These results manifested the possibility of *c-MYC* as a clinically useful indicator in the prognosis of cancer. However, the criteria for *c-MYC* amplification in colorectal cancer have not been unified, and whether it could be an independent prognostic factor in colorectal cancer that has been scarcely investigated. And recent studies provided inconsistent conclusions ([@ref10]). Some early studies revealed the incidence of *c-MYC* amplification in colorectal cancer and found it was associated with tumor invasion and poor prognosis ([@ref14],[@ref15]), but a recent study showed *c-MYC* amplification was unrelated with clinicopathologic features and clinical outcomes ([@ref12]). Therefore, further detailed analysis is needed to confirm the prognostic significance of *c-MYC* amplification in colorectal cancer.

Intriguingly, we observed schistosome eggs under microscope in hematoxylin and eosin (HE) stained slides from our cohort. Qingpu District used to be schistosomiasis endemic areas and majorly infected with *Schistosoma japonicum*. In endemic areas, it is not uncommon to detect schistosome eggs in the intestines of colorectal cancer patients, but the relationship between schistosomiasis and colorectal cancer remains controversial. In Egypt, the reports tend to deny any association of *S. mansoni* and colorectal cancer ([@ref16]). In Asia, *S. japonicum* infection is considered a risk factor for colorectal cancer ([@ref17]). This may be due to the higher egg production of *S. japonicum* female worms and that the eggs are laid in large aggregates that induce intensive tissue reactions in host organs ([@ref18]).

Here, we analyzed *c-MYC* amplification status in 354 colorectal cancer patients using tissue microarrays (TMA) by FISH, and compared its amplification in patients with schistosomiasis and without schistosomiasis groups. Besides, we also compared *c-MYC* amplification status in different stage and different state of lymph node metastasis. We investigated correlations between *c-MYC* amplification status and prognosis in colorectal cancer.

Materials and methods {#sec2}
=====================

Patients and samples {#sec3}
--------------------

The whole cohort was consisted by 354 colorectal cancer patients who underwent surgical resection from Qingpu Branch of Zhongshan Hospital affiliated to Fudan University, from January 2008 to August 2016. None of them received preoperative chemotherapy or radiation therapy. Clinical follow-up data and clinicopathological characteristics, such as age, gender, tumor site, clinical stage, were obtained from medical records and pathologic reports. Two expert pathologists reviewed HE-stained slides to determine the diagnosis and to restage the tumors according to the eighth edition of American Joint Committee on Cancer (AJCC). The diagnosis of schistosomiasis was done by finding schistosome eggs in HE-stained slides.

The present study has been carried out in accordance with the Declaration of Helsinki and was approved by the local institution's Human Research Ethics Committee. Prior written informed consent was obtained from all patients.

Tissue microarrays {#sec4}
------------------

The TMA blocks were manufactured from the most representative areas of individual paraffin blocks, as previously described ([@ref19]). Briefly, reviewed HE-stained slides and marked the represented areas in tumor tissues, and the single core (2-mm wide and 6-mm long) for each case was precisely arrayed into a new recipient paraffin block. The cores containing \>20% tumor cells were considered as valid cores.

Fluorescence *in situ* hybridization (FISH) {#sec5}
-------------------------------------------

FISH for *c-MYC* amplification was performed on the TMA sections of 4-μm thickness by using commercial available probe (*MYC* (8q24) Probe, lot: 201812001, LBP Medicine Science and Technology Company, LTD, Guangzhou, China). *c-MYC* probe would hybridize to the band 8q with Spectrum Red signal, *CEP8* probe would hybridize to the centromeric region of chromosome 8 with Spectrum Green signal.

The FISH slides were interpreted by two experienced evaluators with a fluorescence microscope (Olympus BX43, Olympus Optical Company, LTD, Tokyo, Japan) ([Fig. 1A](#f1){ref-type="fig"} and B). A ratio of the total number of *c-MYC* signals to the total number of *CEP8* signals in at least 60 non-overlapping tumor nuclei was determined. Cells with no signals or with signals of only one color were disregarded. When the red *c-MYC* signals were clearly amplified (large clouds of amplification), we assigned 20 red signals and counted the green *CEP8* signals. For such cases, the ratio was defined as 20 divided by the average number of green signals per cell. *c-MYC*:*CEP8* ratio ≥1.8 was considered as the criterion for gene amplification ([@ref20]).

![(A-B) Representative patterns of c-MYC gene by FISH (oil immersion, ×1000). (A) *c-MYC* amplification (c-MYC:CEP8 ratio = 9.03). (B) c-MYC gene disomy (c-MYC:CEP8 ratio = 0.97). (C) Typical sample of schistosomiasis-associated colorectal cancer, the red arrows indicate schistosome eggs (HE, ×100). (D) Positive staining for c-MYC showed frequent nuclear expression (×200).](hyz210f1){#f1}

Immunohistochemistry (IHC) {#sec6}
--------------------------

IHC labeling was performed as previously described ([@ref21]) by Ascend Aliya autostainer (Ascend microsystems, Guangzhou, China), using a commercially available rabbit monoclonal c-MYC antibody (clone EP121, lot: 180712803C1, MXB Biotechnologies, Fuzhou, China). c-MYC expression was evaluated by two pathologists independently, who were blinded to clinic data. The percentage of positively stained cells and staining intensity were all evaluated. When nucleus of strong and moderate staining in \>10% of the neoplastic cells, it was regarded as positive. Otherwise, the results were recorded as negative ([@ref10]).

Statistical analysis {#sec7}
--------------------

The association between c-MYC status and clinicopathological characteristics was evaluated by using the Chi square and Fisher's exact tests. Overall survival (OS) was defined as the time of surgery to death. Kaplan--Meier curves with log-rank tests were used to determine the prognostic significance for OS, and multivariate Cox proportional hazard regression analysis was used to identify the independent prognostic factors. All statistical analyses were performed by using SPSS version 20.0 and GraphPad prism 7.0. *P* values \<0.05 were considered statistically significant.

Results {#sec8}
=======

Patient characteristics {#sec9}
-----------------------

The clinicopathologic characteristics of the study cohort are summarized in [Table 1](#TB1){ref-type="table"}. Among these patients, 39.0% (138 out of 354) had schistosomiasis ([Table 1](#TB1){ref-type="table"} and [Fig. 1C](#f1){ref-type="fig"}). The median age of patients with schistosomiasis was 74 years (CRC-S, range 54--91), and age of patients without schistosomiasis was 64 years (CRC-NS, range 33--90). The differences of clinicopathologic characteristics between CRC-S set and CRC-NS set were summarized in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. There was no magnificent difference between two sets except for age (*P* \< 0.001, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

###### 

The association between clinicopathological characteristics and c-MYC status in full cohort of colorectal cancer patients (*N* = 354)

  Characteristics                                 All patients   *c-MYC* amplification   *P* values   c-MYC IHC   *P* values              
  ----------------------------------------------- -------------- ----------------------- ------------ ----------- ------------ ---- ----- -------
  Age                                                                                                             0.028                   0.627
   \<60                                           84             23.7                    66           18                       25   59    
    ≥ 60                                          270            76.3                    238          32                       88   182   
  Gender                                                                                                          0.775                   0.036
   Female                                         141            39.8                    122          19                       36   105   
   Male                                           213            60.2                    182          31                       77   136   
  Tumor site                                                                                                      0.077                   0.460
   Rectum                                         96             27.1                    80           16                       28   68    
   Left-sided                                     115            32.5                    94           21                       34   81    
   Right-sided                                    143            40.4                    130          13                       51   92    
  Tumor size[^a^](#tblfn1){ref-type="table-fn"}                                                                   0.075                   0.269
   \<5 cm                                         174            49.2                    144          30                       50   124   
    ≥5 cm                                         154            43.5                    138          16                       53   101   
  Differentiation                                                                                                 0.756                   0.165
   Low                                            84             23.7                    73           11                       81   189   
   High                                           270            76.3                    231          39                       32   52    
  Invasive depth                                                                                                  0.211                   0.033
   I + II                                         81             22.9                    73           8                        18   63    
   III                                            273            77.1                    231          42                       95   178   
  Lymph node metastasis                                                                                           0.004                   0.747
   No                                             208            58.8                    188          20                       65   143   
   Yes                                            146            41.2                    116          30                       48   98    
  Clinical stage                                                                                                  0.002                   0.889
   I + II                                         193            54.5                    176          17                       61   132   
   III + IV                                       161            45.5                    128          33                       52   109   
  Schistosomiasis                                                                                                 0.878                   0.344
   No                                             216            61.0                    185          31                       73   143   
   Yes                                            138            39.0                    119          19                       40   98    

^a^: Missing data.

Abbreviation: IHC, immunohistochemistry; Pos, positive; Neg, negative.

Invasive depth I = confined to submucosal layer; Invasive depth II = invasion of muscular layer; Invasive depth III = beyond the adventitia. *P* values are calculated by using the Chi square and Fisher's exact test.

c-MYC status and correlation with clinicopathologic features {#sec10}
------------------------------------------------------------

The median of *c-MYC*:*CEP8* ratio identified by FISH was 1.20 (range of 0.83--9.03). In present study, results demonstrated that *c-MYC* amplification was detected in 14.1% (50 out of 354) of patients ([Fig. 1A](#f1){ref-type="fig"}) by defining the *c-MYC* amplification as *c-MYC*:*CEP8* ≥1.8. There was no difference between CRC-S set and CRC-NS set in the distribution of *c-MYC*:*CEP8* ratio ([Fig. 2A](#f2){ref-type="fig"}). [Table 1](#TB1){ref-type="table"} showed the correlation between *c-MYC* amplification status and clinicopathologic features in total of 354 patients. Briefly, *c-MYC* amplification was linked with young age (*P* = 0.028), positive lymph node metastasis (*P* = 0.004) and advanced stage (*P* = 0.002). Overexpression of c-MYC was observed in 68.1% (241 out of 354) of full cohort ([Fig. 1D](#f1){ref-type="fig"}) and associated with male (*P* = 0.036) and deeper invasive depth (*P* = 0.033). There were 82% (41 out of 50) *c-MYC* amplification samples showed strong nuclear protein expression, by statistical analysis, the nuclear expression of c-MYC was significantly related with gene amplification (*P* = 0.023) (data not showed).

![(A) Distribution of c-MYC:CEP8 ratio in CRC-NS set. (B--F) Kaplan--Meier survival curves illustrating prognostic effects of *c-MYC* amplification in CRC. (B) *c-MYC* amplification for OS in full cohort. (C) *c-MYC* amplification for OS in stage I-II set. (D) *c-MYC* amplification for OS in stage III-IV set. (E) *c-MYC* amplification for OS in patients without lymph node metastasis. (F) *c-MYC* amplification for OS in patients with lymph node metastasis.](hyz210f2){#f2}

Survival analyses in full cohort of patients with colorectal cancer {#sec11}
-------------------------------------------------------------------

The median follow-up times were 62.4 months (range from 0.4 to 134.4 months). During the follow up, there were 41.8% (148 out of 354) patients died. Mean and median times to OS were 62.63 and 62.49 months, respectively.

A Kaplan--Meier curve for OS showed *c-MYC* amplification was significantly associated with poor survival in total colorectal cancer patients (*P* = 0.002) ([Fig. 2B](#f2){ref-type="fig"}). Univariate analyses involving Cox proportional hazards models showed that age, gender, invasive depth, lymph node metastasis, clinical stage, differentiation, schistosomiasis and *c-MYC* amplification had association with OS ([Table 2](#TB2){ref-type="table"}). In multivariate analysis for OS, age, gender, clinical stage, differentiation and *c-MYC* amplification were identified as independent poor prognostic factors.

###### 

Univariate and multivariate survival analyses of clinicopathological and molecular features for overall survival (OS)

  Variable                All patients   Patients with stage I-II disease   Patients with stage III-IV disease   Patients with lymph node metastasis   Patients without lymph node metastasis                                                                   
  ----------------------- -------------- ---------------------------------- ------------------------------------ ------------------------------------- ---------------------------------------- ---------------------- ------- ---------------------- --------- ---------------------
  Univariate analysis                                                                                                                                                                                                                                           
  Age                     0.006          1.828(1.188--2.814)                0.008                                3.516(1.397--8.847)                   0.167                                    1.419(0.864--2.328)    0.074   1.624(0.953--2.765)    0.021     2.397(1.138--5.047)
  Gender                  0.009          1.582(1.119--2.237)                0.071                                1.761(0.954--3.252)                   0.011                                    1.735(1.136--2.649)    0.012   1.787(1.137--2.809)    0.142     1.501(0.873--2.581)
  Tumor site                                                                                                                                                                                                                                                    
   Rectum                                Reference                                                               Reference                                                                      Reference                      Reference                        Reference
   Left colon             0.931          1.019(0.674--1.540)                0.672                                1.167(0.571--2.383)                   0.863                                    0.956(0.575--1.590)    0.955   0.985(0.581--1.670)    0.940     1.026(0.527--1.996)
   Right colon            0.531          0.879(0.589--1.314)                0.991                                1.004(0.503--2.006)                   0.457                                    0.827(0.502--1.363)    0.265   0.739(0.434--1.258)    0.868     1.054(0.565--1.965)
  Tumor size              0.550          1.108(0.792--1.549)                0.954                                1.017(0.573--1.804)                   0.389                                    1.199(0.793--1.813)    0.165   1.359(0.881--2.098)    0.627     0.876(0.515--1.492)
  Invasive depth          \<0.001        2.628(1.585--4.357)                0.648                                1.150(0.631--2.097)                   0.005                                    7.496(1.846--30.445)   0.007   6.922(1.702--28.156)   0.276     1.383(0.772--2.478)
  Lymph node metastasis   \<0.001        2.717(1.956--3.774)                0.048                                4.184(1.010--17.335)                  0.562                                    0.830(0.442--1.558)    ---     ---                    ---       ---
  Clinical stage          \<0.001        3.109(2.215--4.365)                ---                                  ---                                   ---                                      ---                    0.828   0.856(0.210--3.484)    \<0.001   4.110(2.121--7.967)
  Differentiation         0.001          1.846(1.305--2.611)                0.897                                1.051(0.495--2.233)                   0.012                                    1.690(1.123--2.541)    0.128   1.402(0.907--2.167)    0.086     1.687(0.929--3.066)
  Schistosomiasis         0.041          1.402(1.014--1.940)                0.405                                1.262(0.730--2.182)                   0.020                                    1.627(1.080--2.452)    0.020   1.663(1.083--2.555)    0.345     1.276(0.770--2.115)
  *c-MYC* amplification   0.002          1.912(1.266--2.887)                0.604                                1.276(0.507--3.210)                   0.036                                    1.653(1.032--2.646)    0.014   1.839(1.132--2.990)    0.640     1.223(0.526--2.843)
  c-MYC IHC               0.064          0.732(0.526--1.019)                0.400                                0.786(0.449--1.376)                   0.079                                    0.692(0.459--1.043)    0.130   0.717(0.467--1.103)    0.330     0.773(0.460--1.298)
  Multivariate analysis                                                                                                                                                                                                                                         
  Age                     0.020          2.021(1.297--3.147)                0.005                                3.874(1.519--9.883)                   ---                                      ---                    ---     ---                    0.022     2.390(1.133--5.041)
  Gender                  0.008          1.603(1.128--2.277)                ---                                  ---                                   0.032                                    1.592(1.041--2.435)    0.048   1.586(1.004--2.503)    ---       ---
  Invasive depth          ---            ---                                ---                                  ---                                   0.006                                    7.271(1.783--29.647)   0.010   6.293(1.543--25.668)   ---       ---
  Lymph node metastasis   ---            ---                                0.011                                6.607(1.541--28.326)                  ---                                      ---                    ---     ---                    ---       ---
  Clinical stage          \<0.001        2.639(1.849--3.765)                ---                                  ---                                   ---                                      ---                    ---     ---                    \<0.001   4.105(2.111--7.982)
  Differentiation         0.006          1.664(1.161--2.384)                ---                                  ---                                   0.003                                    1.900(1.245--2.901)    ---     ---                    ---       ---
  Schistosomiasis         ---            ---                                ---                                  ---                                   0.011                                    1.701(1.128--2.565)    0.025   1.634(1.064--2.510)    ---       ---
  *c-MYC* amplification   0.002          1.966(1.278--3.027)                ---                                  ---                                   0.018                                    1.790(1.107--2.896)    0.021   1.775(1.089--2.893)    ---       ---

---, not applicable

Abbreviation: CI, confidence interval.

Survival analyses based on clinical stage {#sec12}
-----------------------------------------

In stage I-II set (*n* = 193), no correlation was found between *c-MYC* amplification and prognosis (*P* = 0.604) ([Fig. 2C](#f2){ref-type="fig"}). However, in stage III-IV set (*n* = 161), *c-MYC* amplification was correlated with poor survival (*P* = 0.034) ([Fig. 2D](#f2){ref-type="fig"}). In univariate analyses for OS, gender, invasive depth, differentiation, schistosomiasis and *c-MYC* amplification were significant prognostic factors. In multivariate analysis with *c-MYC* amplification and conventional significant variables, *c-MYC* amplification was a significant prognostic factor for OS (*P* = 0.018, HR = 1.790, 95%CI, 1.107--2.896) ([Table 2](#TB2){ref-type="table"}).

Survival analyses based on lymph node metastasis status {#sec13}
-------------------------------------------------------

In patients without lymph node metastasis, *c-MYC* amplification was not associated with OS ([Table 2](#TB2){ref-type="table"} and [Fig. 2E](#f2){ref-type="fig"}). In patients with lymph node metastasis (*n* = 146), *c-MYC* amplification was observed in 20.5% (30 out of 146) and associated with poor survival (*P* = 0.012) ([Table 1](#TB1){ref-type="table"} and [Fig. 2F](#f2){ref-type="fig"}). By using univariate and multivariate analysis, *c-MYC* amplification was independently prognostic factor in this subgroup (*P* = 0.021, HR = 1.775, 95%CI, 1.089--2.893) ([Table 2](#TB2){ref-type="table"}).

Survival analyses based on schistosomiasis status {#sec14}
-------------------------------------------------

During the follow up, there was 47.8% (66 out of 138) patients died in CRC-S set, 38.0% (82 out of 216) patients died in CRC-NS set. Mean and median times to OS in CRC-S set were 56.49 and 49.97 months, respectively. The CRC-NS set were 66.45 and 67.93 months, respectively.

In CRC-S set, Kaplan--Meier curve for OS showed *c-MYC* amplification was correlated with poor survival (*P* \< 0.001) ([Fig. 3A](#f3){ref-type="fig"}). Univariate analyses showed that lymph node metastasis, clinical stage and *c-MYC* amplification were associated with OS ([Table 3](#TB3){ref-type="table"}). Owing to age as a known factor was associated with survival or prognosis, and most patients' age were over 60 years old (133 out of 138), age was not included in univariate analysis. In multivariate analysis for OS, clinical stage and *c-MYC* amplification were the only factors manifested statistical significance (*P* \< 0.001, HR = 3.640, 95%CI, 2.143--6.183; *P* = 0.046, HR = 1.861, 95%CI, 1.012--3.419, respectively) ([Table 3](#TB3){ref-type="table"}). Further analyses in CRC-S subsets stratified by clinical stage and lymph node metastasis showed that patients with *c-MYC* amplification tend to be poor prognosis in stage III-IV set and patients with lymph node metastasis (*P* = 0.068, 0.024, respectively) ([Fig. 3B](#f3){ref-type="fig"}--E), which were similar with the results in full cohort.

![Kaplan--Meier survival curves illustrating prognostic effects of *c-MYC* amplification in CRC-S set and CRC-NS set. (A and F) *c-MYC* amplification for OS in CRC-S set and CRC-NS set. (B and C) *c-MYC* amplification for OS in CRC-S with stage I-II or stage III or IV. (D and E) *c-MYC* amplification for OS in CRC-S without or with lymph node metastasis. (G and H) *c-MYC* amplification for OS in CRC-NS with stage I-II or stage III-IV. (I and J) *c-MYC* amplification for OS in CRC-NS without or with lymph node metastasis.](hyz210f3){#f3}

###### 

Univariate and multivariate survival analyses for OS in CRC-S set and CRC-NS set

  Variable                Patients with schistosomiasis   Patients without schistosomiasis             
  ----------------------- ------------------------------- ---------------------------------- --------- ---------------------
  Univariate analysis                                                                                  
  Age                     ---                             ---                                0.090     1.506(0.939--2.416)
  Gender                  0.392                           1.251(0.749--2.088)                0.011     1.839(1.148--2.945)
  Tumor site                                                                                           
   Rectum                                                 Reference                                    Reference
   Left colon             0.487                           1.261(0.656--2.4223)               0.653     0.884(0.515--1.516)
   Right colon            0.104                           1.687(0.898--3.168)                0.050     0.587(0.345--1.000)
  Tumor size              0.072                           1.574(0.960--2.582)                0.578     0.876(0.549--1.397)
  Invasive depth          0.079                           1.882(0.930--3.805)                0.001     3.401(1.640--7.056)
  Lymph node metastasis   \<0.001                         3.391(2.055--5.595)                \<0.001   2.441(1.572--3.790)
  Clinical stage          \<0.001                         3.998(2.384--6.704)                \<0.001   2.753(1.749--4.335)
  Differentiation         0.066                           1.627(0.968--2.734)                0.004     1.985(1.246--3.164)
  *c-MYC* amplification   0.001                           2.719(1.504--4.918)                0.158     1.515(0.852--2.694)
  c-MYC IHC               0.454                           0.824(0.496--1.368)                0.062     0.659(0.425--1.022)
  Multivariate analysis                                                                                
  Gender                  ---                             ---                                0.009     1.875(1.167--3.012)
  Invasive depth          ---                             ---                                0.017     2.477(1.177--5.216)
  Clinical stage          \<0.001                         3.640(2.143--6.183)                \<0.001   2.527(1.588--4.019)
  Differentiation         ---                             ---                                ---       ---
  *c-MYC* amplification   0.046                           1.861(1.012--3.419)                ---       ---

---, not applicable

Abbreviation: CI, confidence interval.

However, in CRC-NS set (*n* = 216), no correlation was found between *c-MYC* amplification and prognosis in total or in the subsets stratified by clinical stage or lymph node metastasis status ([Table 3](#TB3){ref-type="table"}, [Fig. 3](#f3){ref-type="fig"}F--J).

Discussion {#sec15}
==========

The *c-MYC* gene encodes nuclear DNA binding proteins that regulate the expression of a variety of genes implicated in cell proliferation, apoptosis, metabolism, stemness, invasiveness and inhibition of differentiation ([@ref22],[@ref23]). In general, c-MYC dysregulation in lymphoma is usually caused by chromosome translocation and is typically associated with aggressive clinical behavior. Similarly, *c-MYC* amplification is clearly correlated with adverse biological features of the tumors. A previous study of chondrosarcoma showed that *c-MYC* amplification was prognostic markers of poor outcome for chondrosarcomas of grade 2 or higher ([@ref10]). Another study found an association between *c-MYC* amplification and disease progression in prostate cancer ([@ref7]).

However, the research about association between *c-MYC* amplification and colorectal cancer was really rare. In our study, we found that *c-MYC* amplification was detected in 14.1% (50 out of 354) of patients with colorectal cancer, and *c-MYC* amplification was related to poor prognosis in full cohort. Further study showed that *c-MYC* amplification was also a poor predictor in schistosomiasis-associated colorectal cancer, but was not in colorectal cancer without schistosomiasis.

According to previously published reports, the frequency of *c-MYC* amplification in colorectal cancer was \~8--14% ([@ref12],[@ref24]), this was consistent with our result, which was 14.1%. Masramon's results showed that *c-MYC* amplification was correlated with shorter disease-free survival ([@ref14]), whereas the other studies showed that not *c-MYC* amplification ([@ref12]) but *c-MYC* copy number gain can be a poor prognostic factor in colorectal cancer ([@ref13],[@ref25]). In our study, *c-MYC* amplification was correlated with poor prognosis in the whole cohort ([Fig. 2B](#f2){ref-type="fig"}), which was inconsistent with previous reports. The unexpectedly discovered schistosome eggs reminded us that this may contributed to the inconsistence. Hence, further subgroups were generated based on schistosomiasis, the total cohort was divided into two groups: CRC-S and CRC-NS. Interestingly, we found that *c-MYC* amplification could predict poor prognosis in schistosomiasis-associated colorectal cancer, but not in colorectal cancer without schistosomiasis ([Fig. 3A](#f3){ref-type="fig"}). These findings, therefore, suggest that *c-MYC* amplification may involve in the pathogenesis and mechanism of schistosomiasis-associated colorectal cancer. The overexpression of c-MYC was not associated with OS in CRC-S set or CRC-NS set ([Table 3](#TB3){ref-type="table"}). Although there was a weak correlation between c-MYC protein overexpression and *c-MYC* amplification, *c-MYC* amplification was not detected in most c-MYC protein overexpression cases, suggesting that there are alternative mechanisms responsible for c-MYC protein overexpression, rather than just gene amplification. The potential mechanisms including single nucleotide polymorphism in regulatory regions, mutation of upstream signaling pathways and mutations that enhance the stability of the protein ([@ref26]). Further research is needed to explore the association of c-MYC overexpression and gene amplification in schistosomiasis-associated colorectal cancer.

*Schistosoma haematobium*, *S. mansoni* and *S. japonicum* are three main species of schistosomes that infect human beings. In China, the majority of schistosomes that infect human are *S. japonicum*. Historically, Qingpu District was one of serious schistosomiasis endemic areas between 1940s and 1960s, 154 767 of the 390 000 people in Qingpu District were suffering from schistosomiasis, with an infection rate of \~39% ([@ref29]). Although through effective prevention and treatment, Qingpu District had reached the standard of schistosomiasis elimination in 1983, the effects of schistosomiasis still exist. All evidence suggests that schistosome eggs, and not adult worms, induce the host's immune response and the granulomatous reaction ([@ref30]). Many eggs permanently deposit in the intestines or liver (for *S. mansoni* and *S. japonicum*) or in the bladder and urogenital system (for *S. haematobium*). At present, there is solid evidence to confirm that *S. haematobium* is strongly associated with squamous cell carcinoma of the bladder ([@ref31]). The International Agency for Research on Cancer (IARC) has regarded the infection with *S. haematobium* as Group 1 carcinogen ([@ref32]). Similarly, other macroparasites such as the liver flukes *Opisthorchis viverrini* and *Clonorchis sinensis* have a role in causing some type of cholangiocarcinoma ([@ref32]). Direct and indirect mechanisms may cause these parasites to be associated with specific tumors ([@ref33]). The relationship between *S. japonicum* and colorectal cancer remains controversial. Although many studies showed that there is a strong association between *S. japonicum* and colorectal cancer, there is no definite evidence that *S. japonicum* is a causative agent in the development of colorectal cancer ([@ref34],[@ref35]).

After infection with *S. japonicum*, schistosome eggs will deposit in the digestive tract, release of egg antigen, and the process of granulomas formation will be accompanied by chronic inflammation ([@ref36]). The vast majority of the burden of disease due to *S. japonicum* appears to be caused by chronic inflammation ([@ref37]). As a hallmark of cancer, inflammation may cause the formation of tumor. During the process of schistosomal infection, inflammatory cells can generate potential genotoxic mediators such as reactive oxygen and nitrogen species and proinflammatory cytokines, which induce genomic instability and dysregulation of oncogenes and tumor-suppressor genes ([@ref32],[@ref38]). Chromosome region 8q24 including *c-MYC* and *PRL-3* loci, as one category of genomic instability ([@ref39]), is the most commonly amplified region in multiple cancer types, including colorectal cancer ([@ref7],[@ref40]). When chronic inflammation and gene amplification co-exist in CRC-S set, we speculate that the accumulation of molecular disturbance may drive the progression toward dysplasia and carcinoma, even leading to a worse prognosis.

Besides, c-MYC is frequently dysregulated in inflammation and overexpressed in both sporadic and colitis-associated colon adenocarcinomas. Some studies revealed that c-MYC dysregulation functionally contributes to colitis-associated cancer progression ([@ref43],[@ref44]). In inflammatory bowel disease (IBD)-associated intestinal adenocarcinoma, the frequency of *c-MYC* amplification increases to 26--33% ([@ref45],[@ref46]). Yaeger et al. hypothesized that the infrequent WNT pathway activation in IBD-associated intestinal adenocarcinomas provides a selective drive for *c-MYC* gene amplification ([@ref45]). Besides, recent research indicates a tight junction-associated protein, blood vessel epicardial substance (BVES), which promotes inflammatory tumorigenesis through dysregulation of WNT pathway and the oncogene c-MYC ([@ref47]). To fully elucidate the association between c-MYC and schistosomiasis-associated colorectal cancer, it is essential to further investigate the roles of c-MYC, its regulators, its downstream effectors and the relationship between inflammation and schistosomiasis-associated colorectal cancer.

As the first limitation of the present study, we need more bench to lab work to validate the relationship between *c-MYC* and schistosomiasis and to interpret how schistosomiasis exert impact on *c-MYC* amplification. Second, the criterion of *c-MYC* amplification was diverse in different tumors ([@ref7],[@ref10],[@ref20]). The optimal *c-MYC* amplification cutoff value for the prediction of prognosis remains to be established. Third, the proportion of schistosomiasis-associated colorectal cancer patients analyzed herein is \<40%, so that the number of patients in subgroup was too small to draw a definitive conclusion. Therefore, we will increase sample size to validate the clinical meaning of *c-MYC* amplification in further study.

In summary, we first found *c-MYC* amplification was an adverse prognostic factor in schistosomiasis-associated colorectal cancer. These findings might shed light on detailed risk stratification in patients with colorectal cancer and provide an insight into pathogenesis and mechanism of progression in schistosomiasis-associated colorectal cancer.
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